Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Aytu Biopharma Inc's Business Segments
Aytu Biopharma Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2026
Reportable Segments
1
Largest Segment
Rx Segment
Total Revenue
$ 12
Regions Reported
-
Revenue Share by Reportable Segment - Q3 FY2026
- Rx Segment0%
Revenue by Reportable Segment - Q3 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Rx Segment | $ 12 | - |
Revenue by Product & Service Category - Q3 FY2026
- ADHD Portfolio78.4%
- Exxua Portfolio20.7%
- The Pediatric Portfolio7.9%
Revenue by Product & Service Category - Q3 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| ADHD Portfolio | $ 9 | 78.4% |
| Exxua Portfolio | $ 2 | 20.7% |
| The Pediatric Portfolio | $ 1 | 7.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Aytu Biopharma Inc
Aytu BioPharma Inc. is a specialty pharmaceutical company that focuses on developing and commercializing innovative products in the areas of urology, women's health, and sleep disorders. The company is headquartered in Englewood, Colorado and was founded in 201
The company's urology product portfolio includes Natesto, a nasal testosterone replacement therapy (TRT) for adult males diagnosed with hypogonadism; ProstaScint, a radioactive imaging agent for prostate cancer detection; and MiOXSYS, a male infertility diagnostic platform that measures oxidative stress levels in semen samples.
In the women's health sector, Aytu BioPharma produces Tuzistra XR, an extended-release cough syrup designed to treat acute coughing symptoms. The company also recently acquired a product called ZolpiMist, a prescription sleep aid that delivers a fine mist of zolpidem tartrate, which is a sedative-hypnotic drug.
Aytu BioPharma has a diverse and robust pipeline of products in various stages of development that target diseases in urology, endocrinology, and infectious diseases. The company has several strategic collaborations, including a licensing agreement with Acerus Pharmaceuticals for the distribution of Natesto in Canada and a partnership with Innovus Pharmaceuticals for the development and commercialization of products in women's health.
Aytu BioPharma is committed to improving patient outcomes by providing innovative and effective treatments for unmet medical needs. The company has a strong financial position, with a cash balance of $24 million as of June 30, 2020, and has recently reported positive revenue growth. Additionally, Aytu BioPharma has been actively involved in efforts to combat COVID-19, with the distribution of a rapid COVID-19 test and the acquisition of certain assets from Cerecor Inc. for the development of a COVID-19 treatment.
The company's urology product portfolio includes Natesto, a nasal testosterone replacement therapy (TRT) for adult males diagnosed with hypogonadism; ProstaScint, a radioactive imaging agent for prostate cancer detection; and MiOXSYS, a male infertility diagnostic platform that measures oxidative stress levels in semen samples.
In the women's health sector, Aytu BioPharma produces Tuzistra XR, an extended-release cough syrup designed to treat acute coughing symptoms. The company also recently acquired a product called ZolpiMist, a prescription sleep aid that delivers a fine mist of zolpidem tartrate, which is a sedative-hypnotic drug.
Aytu BioPharma has a diverse and robust pipeline of products in various stages of development that target diseases in urology, endocrinology, and infectious diseases. The company has several strategic collaborations, including a licensing agreement with Acerus Pharmaceuticals for the distribution of Natesto in Canada and a partnership with Innovus Pharmaceuticals for the development and commercialization of products in women's health.
Aytu BioPharma is committed to improving patient outcomes by providing innovative and effective treatments for unmet medical needs. The company has a strong financial position, with a cash balance of $24 million as of June 30, 2020, and has recently reported positive revenue growth. Additionally, Aytu BioPharma has been actively involved in efforts to combat COVID-19, with the distribution of a rapid COVID-19 test and the acquisition of certain assets from Cerecor Inc. for the development of a COVID-19 treatment.
Aytu BioPharma Inc. is a prominent U.S.-based specialty pharmaceutical company that focuses on the licensing, development, and commercialization of innovative products tailored to the fields of health and wellness. The firm aims to address the specific needs of both the medical community and patients, enhancing the quality of care through more effective and personalized therapies.
Segments
Aytu BioPharma operates primarily in two key segments:
1. Prescription Therapeutics: This segment encompasses the companys prescription-based products, which are aimed at treating various medical conditions. These therapeutic options are designed for utilization by healthcare professionals in clinical settings. The main products within this segment include:
- Natesto
- ZolpiMist
- Tuzistra XR
2. Consumer Health: This segment includes over-the-counter (OTC) products aimed at promoting general health and wellness for consumers. Aytu BioPharmas consumer health offerings focus on dietary supplements designed to support various health needs. The prominent product in this category includes:
- MiOXSYS
Products and Services
Aytu BioPharmas diverse range of products and services is designed to provide targeted solutions in healthcare:
1. Natesto: Natesto is a unique testosterone replacement therapy (TRT) specifically formulated for men diagnosed with hypogonadism, a condition characterized by insufficient testosterone production. Unlike traditional TRT formulations, Natesto is delivered through a convenient nasal gel, allowing for rapid absorption and maintaining testosterone levels effectively within the body. This non-invasive delivery method provides patients with an alternative to injections or oral medications.
2. ZolpiMist: ZolpiMist is an advanced sleep aid notable for its convenient oral spray delivery system. Containing Zolpidem, a well-established sedative-hypnotic medication, ZolpiMist is engineered to assist individuals suffering from insomnia, particularly those who face challenges with falling or staying asleep. This formulation aims to improve the quality and duration of sleep with a more immediate onset of action than traditional pill forms.
3. Tuzistra XR: Tuzistra XR is a prescription cough syrup designed for the alleviation of cough symptoms associated with upper respiratory allergies or the common cold. The formulation combines codeine, an opioid cough suppressant, with chlorpheniramine, an antihistamine that mitigates allergy-related symptoms. This combination works synergistically to provide relief from coughing while also addressing other common cold symptoms.
4. MiOXSYS: Aytu BioPharmas MiOXSYS product line consists of dietary supplements aimed at supporting male fertility. The MiOXSYS formula is enriched with antioxidants and other essential nutrients that contribute to healthy sperm production and function. This product serves as an essential component for men looking to enhance their reproductive health.
5. Diagnostic Testing Services: In addition to its primary products, Aytu BioPharma also offers advanced diagnostic testing services, including the MiOXSYS System. This innovative medical device measures oxidative stress levels in semen, providing valuable insights into male fertility and reproductive health. By assessing oxidative stress, healthcare providers can better understand factors affecting male fertility and offer informed recommendations.
Conclusion
Aytu BioPharma Inc. is dedicated to advancing healthcare through a focused portfolio that spans prescription therapeutics and consumer health. With products like Natesto, ZolpiMist, and Tuzistra XR tailored for specific medical conditions, alongside consumer health supplements like MiOXSYS and diagnostic testing solutions, the company is positioned to address critical healthcare needs effectively. Their commitment to developing and commercializing novel products reflects an ongoing pursuit of personalized and effective care in the healthcare landscape.
Segments
Aytu BioPharma operates primarily in two key segments:
1. Prescription Therapeutics: This segment encompasses the companys prescription-based products, which are aimed at treating various medical conditions. These therapeutic options are designed for utilization by healthcare professionals in clinical settings. The main products within this segment include:
- Natesto
- ZolpiMist
- Tuzistra XR
2. Consumer Health: This segment includes over-the-counter (OTC) products aimed at promoting general health and wellness for consumers. Aytu BioPharmas consumer health offerings focus on dietary supplements designed to support various health needs. The prominent product in this category includes:
- MiOXSYS
Products and Services
Aytu BioPharmas diverse range of products and services is designed to provide targeted solutions in healthcare:
1. Natesto: Natesto is a unique testosterone replacement therapy (TRT) specifically formulated for men diagnosed with hypogonadism, a condition characterized by insufficient testosterone production. Unlike traditional TRT formulations, Natesto is delivered through a convenient nasal gel, allowing for rapid absorption and maintaining testosterone levels effectively within the body. This non-invasive delivery method provides patients with an alternative to injections or oral medications.
2. ZolpiMist: ZolpiMist is an advanced sleep aid notable for its convenient oral spray delivery system. Containing Zolpidem, a well-established sedative-hypnotic medication, ZolpiMist is engineered to assist individuals suffering from insomnia, particularly those who face challenges with falling or staying asleep. This formulation aims to improve the quality and duration of sleep with a more immediate onset of action than traditional pill forms.
3. Tuzistra XR: Tuzistra XR is a prescription cough syrup designed for the alleviation of cough symptoms associated with upper respiratory allergies or the common cold. The formulation combines codeine, an opioid cough suppressant, with chlorpheniramine, an antihistamine that mitigates allergy-related symptoms. This combination works synergistically to provide relief from coughing while also addressing other common cold symptoms.
4. MiOXSYS: Aytu BioPharmas MiOXSYS product line consists of dietary supplements aimed at supporting male fertility. The MiOXSYS formula is enriched with antioxidants and other essential nutrients that contribute to healthy sperm production and function. This product serves as an essential component for men looking to enhance their reproductive health.
5. Diagnostic Testing Services: In addition to its primary products, Aytu BioPharma also offers advanced diagnostic testing services, including the MiOXSYS System. This innovative medical device measures oxidative stress levels in semen, providing valuable insights into male fertility and reproductive health. By assessing oxidative stress, healthcare providers can better understand factors affecting male fertility and offer informed recommendations.
Conclusion
Aytu BioPharma Inc. is dedicated to advancing healthcare through a focused portfolio that spans prescription therapeutics and consumer health. With products like Natesto, ZolpiMist, and Tuzistra XR tailored for specific medical conditions, alongside consumer health supplements like MiOXSYS and diagnostic testing solutions, the company is positioned to address critical healthcare needs effectively. Their commitment to developing and commercializing novel products reflects an ongoing pursuit of personalized and effective care in the healthcare landscape.